Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain Metastases in Differentiated Thyroid Carcinoma: Clinical Features, Treatment Outcomes, and the Role of Radioiodine Therapy.

Clinical endocrinology·2026
Same author

68 Ga-DOTANOC PET/CT in a Case of Grade 1 Pancreatic NET With Renal Vein and Gonadal Vein Tumor Thrombus.

Clinical nuclear medicine·2026
Same author

Interpreting Clonal Hematopoiesis Following [<sup>177</sup>Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

68Ga-PSMA-11 PET/CT Versus Conventional Imaging for Response Evaluation in Metastatic Castration-resistant Prostate Cancer: A Single-center Prospective Study.

Clinical nuclear medicine·2026
Same author

Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN).

Seminars in nuclear medicine·2025
Same author

Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer: A Pilot Study.

Clinical nuclear medicine·2025

Related Experiment Video

Updated: Apr 10, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.9K

Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer - Current State and Evolving Standards.

Swayamjeet Satapathy1, Kunal R Chandekar2, Nishikant A Damle3

  • 1Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre & Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, India.

PET Clinics
|April 8, 2026
PubMed
Summary

Prostate-specific membrane antigen (PSMA)-based theranostics are revolutionizing prostate cancer care. PSMA-ligand PET imaging and [177Lu]Lu-PSMA-617 therapy offer improved diagnostics and treatment, enhancing survival and quality of life for patients.

Keywords:
Lutetium-177PET/CTPSMA radioligand therapyProstate cancerProstate-specific membrane antigen (PSMA)Theranostics

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 10, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Therapy

Background:

  • Prostate-specific membrane antigen (PSMA) theranostics represent a significant advancement in prostate cancer management.
  • PSMA-ligand positron emission tomography (PET)/computed tomography (CT) shows superior diagnostic accuracy compared to conventional imaging.
  • Metastatic castration-resistant prostate cancer (mCRPC) management has been advanced by PSMA-based approaches.

Purpose of the Study:

  • To evaluate the impact of PSMA-based theranostics in prostate cancer management.
  • To highlight the diagnostic and therapeutic advancements offered by PSMA-ligand PET/CT and [177Lu]Lu-PSMA-617.
  • To explore the integration of [177Lu]Lu-PSMA-617 in earlier stages of prostate cancer.

Main Methods:

  • Review of clinical data and phase 3 trial evidence for PSMA-ligand PET/CT and [177Lu]Lu-PSMA-617 therapy.
  • Analysis of diagnostic accuracy of PSMA-ligand PET/CT in various clinical settings.
  • Assessment of survival end points and quality of life improvements with [177Lu]Lu-PSMA-617 therapy.

Main Results:

  • PSMA-ligand PET/CT demonstrates superior diagnostic performance in prostate cancer.
  • [177Lu]Lu-PSMA-617 therapy is established as a standard of care for mCRPC, improving survival and quality of life.
  • Emerging data indicate safe and effective use of [177Lu]Lu-PSMA-617 in earlier disease stages.

Conclusions:

  • PSMA-based theranostics are transforming prostate cancer care.
  • Nuclear medicine plays a vital role in precision oncology for prostate cancer.
  • [177Lu]Lu-PSMA-617 offers significant benefits across different stages of prostate cancer.